Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics has achieved FDA clearance to commence a Phase 2b trial for its novel brain imaging agent, F18-Pivalate (RAD 101), designed to target and potentially monitor brain metastases. This development signifies a substantial step toward addressing the significant medical needs of approximately 300,000 U.S. patients diagnosed with brain metastases annually. The company anticipates initiating patient dosing later this year, with Phase 2b results expected by mid-2025, followed by a Phase 3 study.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
